APO Research
Talk to an analyst

APO RESEARCH · REPORT

Avastin (Bevacizumab) Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Avastin (Bevacizumab) Biosimilars Market Analysis and Forecast 2026-2032

30 December 2025212 pages

Choose your research edition.

Industry ResearchAvastin (Bevacizumab) Biosimilars Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Avastin (Bevacizumab) Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Avastin (Bevacizumab) Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Avastin (Bevacizumab) Biosimilars Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Avastin (Bevacizumab) Biosimilars Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Avastin (Bevacizumab) Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Avastin (Bevacizumab) Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Avastin (Bevacizumab) Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Avastin (Bevacizumab) Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Avastin (Bevacizumab) Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Avastin (Bevacizumab) Biosimilars include Biocad, Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero, Kirin Biologics and MAbxience, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Avastin (Bevacizumab) Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Avastin (Bevacizumab) Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Avastin (Bevacizumab) Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Avastin (Bevacizumab) Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Avastin (Bevacizumab) Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Avastin (Bevacizumab) Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Avastin (Bevacizumab) Biosimilars Segment by Company

Biocad

Biocon

Cadila Pharmaceuticals

Centus

Dr Reddy's

Genentech

Hetero

Kirin Biologics

MAbxience

PharmaPraxis

PlantForm

Samsung Bioepis

Sartorius

Amgen

BeiGene

Bayer

TOT BIOPHARM

Henlius

Pfizer

Eli Lilly

Roche

Luye Pharmaceutical

Mylan

Qilu Pharmaceutical

Innovent

Avastin (Bevacizumab) Biosimilars Segment by Type

Cancers

AMD

Avastin (Bevacizumab) Biosimilars Segment by Application

Hospitals

Clinics

Others

Avastin (Bevacizumab) Biosimilars Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Avastin (Bevacizumab) Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Avastin (Bevacizumab) Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Avastin (Bevacizumab) Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Avastin (Bevacizumab) Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Avastin (Bevacizumab) Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Avastin (Bevacizumab) Biosimilars sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Avastin (Bevacizumab) Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cancers Major Manufacturers Table 3. AMD Major Manufacturers Table 4. Global Avastin (Bevacizumab) Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Major Manufacturers Table 6. Clinics Major Manufacturers Table 7. Others Major Manufacturers Table 8. Avastin (Bevacizumab) Biosimilars Industry Trends Table 9. Avastin (Bevacizumab) Biosimilars Industry Drivers Table 10. Avastin (Bevacizumab) Biosimilars Industry Opportunities and Challenges Table 11. Avastin (Bevacizumab) Biosimilars Industry Restraints Table 12. Global Avastin (Bevacizumab) Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2021-2026) Table 16. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2027-2032) Table 17. Global Avastin (Bevacizumab) Biosimilars Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2026) & (K Units) Table 19. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2027-2032) & (K Units) Table 20. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2021-2026) Table 21. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2027-2032) Table 22. Global Avastin (Bevacizumab) Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Avastin (Bevacizumab) Biosimilars Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 26. Global Avastin (Bevacizumab) Biosimilars Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Avastin (Bevacizumab) Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Avastin (Bevacizumab) Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Avastin (Bevacizumab) Biosimilars Manufacturers, Product Type & Application Table 30. Global Avastin (Bevacizumab) Biosimilars Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Avastin (Bevacizumab) Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Avastin (Bevacizumab) Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2021-2026) Table 37. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2027-2032) Table 38. Global Avastin (Bevacizumab) Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 40. Global Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 41. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2021-2026) Table 42. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2027-2032) Table 43. Global Avastin (Bevacizumab) Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 44. Global Avastin (Bevacizumab) Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 45. Global Avastin (Bevacizumab) Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2021-2026) Table 49. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2027-2032) Table 50. Global Avastin (Bevacizumab) Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 52. Global Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 53. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2021-2026) Table 54. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2027-2032) Table 55. Global Avastin (Bevacizumab) Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 56. Global Avastin (Bevacizumab) Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 57. Biocad Company Information Table 58. Biocad Business Overview Table 59. Biocad Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio Table 61. Biocad Recent Development Table 62. Biocon Company Information Table 63. Biocon Business Overview Table 64. Biocon Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio Table 66. Biocon Recent Development Table 67. Cadila Pharmaceuticals Company Information Table 68. Cadila Pharmaceuticals Business Overview Table 69. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio Table 71. Cadila Pharmaceuticals Recent Development Table 72. Centus Company Information Table 73. Centus Business Overview Table 74. Centus Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Centus Avastin (Bevacizumab) Biosimilars Product Portfolio Table 76. Centus Recent Development Table 77. Dr Reddy's Company Information Table 78. Dr Reddy's Business Overview Table 79. Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio Table 81. Dr Reddy's Recent Development Table 82. Genentech Company Information Table 83. Genentech Business Overview Table 84. Genentech Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio Table 86. Genentech Recent Development Table 87. Hetero Company Information Table 88. Hetero Business Overview Table 89. Hetero Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio Table 91. Hetero Recent Development Table 92. Kirin Biologics Company Information Table 93. Kirin Biologics Business Overview Table 94. Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio Table 96. Kirin Biologics Recent Development Table 97. MAbxience Company Information Table 98. MAbxience Business Overview Table 99. MAbxience Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio Table 101. MAbxience Recent Development Table 102. PharmaPraxis Company Information Table 103. PharmaPraxis Business Overview Table 104. PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio Table 106. PharmaPraxis Recent Development Table 107. PlantForm Company Information Table 108. PlantForm Business Overview Table 109. PlantForm Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio Table 111. PlantForm Recent Development Table 112. Samsung Bioepis Company Information Table 113. Samsung Bioepis Business Overview Table 114. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio Table 116. Samsung Bioepis Recent Development Table 117. Sartorius Company Information Table 118. Sartorius Business Overview Table 119. Sartorius Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio Table 121. Sartorius Recent Development Table 122. Amgen Company Information Table 123. Amgen Business Overview Table 124. Amgen Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio Table 126. Amgen Recent Development Table 127. BeiGene Company Information Table 128. BeiGene Business Overview Table 129. BeiGene Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio Table 131. BeiGene Recent Development Table 132. Bayer Company Information Table 133. Bayer Business Overview Table 134. Bayer Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio Table 136. Bayer Recent Development Table 137. TOT BIOPHARM Company Information Table 138. TOT BIOPHARM Business Overview Table 139. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio Table 141. TOT BIOPHARM Recent Development Table 142. Henlius Company Information Table 143. Henlius Business Overview Table 144. Henlius Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio Table 146. Henlius Recent Development Table 147. Pfizer Company Information Table 148. Pfizer Business Overview Table 149. Pfizer Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio Table 151. Pfizer Recent Development Table 152. Eli Lilly Company Information Table 153. Eli Lilly Business Overview Table 154. Eli Lilly Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio Table 156. Eli Lilly Recent Development Table 157. Roche Company Information Table 158. Roche Business Overview Table 159. Roche Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Roche Avastin (Bevacizumab) Biosimilars Product Portfolio Table 161. Roche Recent Development Table 162. Luye Pharmaceutical Company Information Table 163. Luye Pharmaceutical Business Overview Table 164. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio Table 166. Luye Pharmaceutical Recent Development Table 167. Mylan Company Information Table 168. Mylan Business Overview Table 169. Mylan Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio Table 171. Mylan Recent Development Table 172. Qilu Pharmaceutical Company Information Table 173. Qilu Pharmaceutical Business Overview Table 174. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio Table 176. Qilu Pharmaceutical Recent Development Table 177. Innovent Company Information Table 178. Innovent Business Overview Table 179. Innovent Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio Table 181. Innovent Recent Development Table 182. North America Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 183. North America Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 184. North America Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 185. North America Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 186. North America Avastin (Bevacizumab) Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 187. North America Avastin (Bevacizumab) Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 188. North America Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 189. North America Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 190. North America Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 191. North America Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 192. North America Avastin (Bevacizumab) Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 193. North America Avastin (Bevacizumab) Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 194. North America Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. North America Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. North America Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 198. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 199. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 200. North America Avastin (Bevacizumab) Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 201. North America Avastin (Bevacizumab) Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 202. United States Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 203. Canada Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 204. Europe Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 205. Europe Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 206. Europe Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 207. Europe Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 208. Europe Avastin (Bevacizumab) Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 209. Europe Avastin (Bevacizumab) Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 210. Europe Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 211. Europe Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 212. Europe Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 213. Europe Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 214. Europe Avastin (Bevacizumab) Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 215. Europe Avastin (Bevacizumab) Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 216. Europe Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. Europe Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 218. Europe Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 219. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 220. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 221. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 222. Europe Avastin (Bevacizumab) Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 223. Europe Avastin (Bevacizumab) Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 224. Germany Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 225. France Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 226. U.K. Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 227. Italy Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 228. Netherlands Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 229. China Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 230. China Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 231. China Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 232. China Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 233. China Avastin (Bevacizumab) Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 234. China Avastin (Bevacizumab) Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 235. China Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 236. China Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 237. China Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 238. China Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 239. China Avastin (Bevacizumab) Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 240. China Avastin (Bevacizumab) Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 241. Asia Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 242. Asia Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 243. Asia Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 244. Asia Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 245. Asia Avastin (Bevacizumab) Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 246. Asia Avastin (Bevacizumab) Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 247. Asia Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 248. Asia Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 249. Asia Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 250. Asia Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 251. Asia Avastin (Bevacizumab) Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 252. Asia Avastin (Bevacizumab) Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 253. Asia Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 254. Asia Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 255. Asia Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 256. Asia Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 257. Asia Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 258. Asia Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 259. Asia Avastin (Bevacizumab) Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 260. Asia Avastin (Bevacizumab) Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 261. Japan Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 262. South Korea Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 263. India Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 264. Australia Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 265. China Taiwan Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 266. Southeast Asia Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 267. SAMEA Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 268. SAMEA Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 269. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 270. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 271. SAMEA Avastin (Bevacizumab) Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 272. SAMEA Avastin (Bevacizumab) Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 273. SAMEA Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 274. SAMEA Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 275. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 276. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 277. SAMEA Avastin (Bevacizumab) Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 278. SAMEA Avastin (Bevacizumab) Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 279. SAMEA Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 280. SAMEA Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 281. SAMEA Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 282. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 283. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 284. SAMEA Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 285. SAMEA Avastin (Bevacizumab) Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 286. SAMEA Avastin (Bevacizumab) Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 287. Brazil Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 288. Argentina Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 289. Chile Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 290. Colombia Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 291. Peru Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 292. Saudi Arabia Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 293. Israel Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 294. UAE Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 295. Turkey Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 296. Iran Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 297. Egypt Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Table 298. Key Raw Materials Table 299. Raw Materials Key Suppliers Table 300. Avastin (Bevacizumab) Biosimilars Distributors List Table 301. Avastin (Bevacizumab) Biosimilars Customers List Table 302. Research Programs/Design for This Report Table 303. Authors List of This Report Table 304. Secondary Sources Table 305. Primary Sources List of Figures Figure 1. Avastin (Bevacizumab) Biosimilars Image Figure 2. Global Avastin (Bevacizumab) Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Avastin (Bevacizumab) Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cancers Image Figure 5. AMD Image Figure 6. Global Avastin (Bevacizumab) Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Avastin (Bevacizumab) Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Clinics Image Figure 10. Others Image Figure 11. Global Avastin (Bevacizumab) Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Figure 13. Global Avastin (Bevacizumab) Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2021-2032) Figure 16. Global Avastin (Bevacizumab) Biosimilars Sales (2021-2032) & (K Units) Figure 17. Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Avastin (Bevacizumab) Biosimilars Sales YoY (2021-2032) & (K Units) Figure 20. Europe Avastin (Bevacizumab) Biosimilars Sales YoY (2021-2032) & (K Units) Figure 21. China Avastin (Bevacizumab) Biosimilars Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Avastin (Bevacizumab) Biosimilars Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales YoY (2021-2032) & (K Units) Figure 24. Global Avastin (Bevacizumab) Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Avastin (Bevacizumab) Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2021-2032) Figure 30. Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2021-2032) Figure 33. Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2021-2032) Figure 36. Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2021-2032) Figure 39. North America Avastin (Bevacizumab) Biosimilars Revenue Share by Type (2021-2032) Figure 40. North America Avastin (Bevacizumab) Biosimilars Sales Share by Type (2021-2032) Figure 41. North America Avastin (Bevacizumab) Biosimilars Revenue Share by Application (2021-2032) Figure 42. North America Avastin (Bevacizumab) Biosimilars Sales Share by Application (2021-2032) Figure 43. North America Avastin (Bevacizumab) Biosimilars Revenue Share by Country (2021-2032) Figure 44. North America Avastin (Bevacizumab) Biosimilars Sales Share by Country (2021-2032) Figure 45. Europe Avastin (Bevacizumab) Biosimilars Revenue Share by Type (2021-2032) Figure 46. Europe Avastin (Bevacizumab) Biosimilars Sales Share by Type (2021-2032) Figure 47. Europe Avastin (Bevacizumab) Biosimilars Revenue Share by Application (2021-2032) Figure 48. Europe Avastin (Bevacizumab) Biosimilars Sales Share by Application (2021-2032) Figure 49. Europe Avastin (Bevacizumab) Biosimilars Revenue Share by Country (2021-2032) Figure 50. Europe Avastin (Bevacizumab) Biosimilars Sales Share by Country (2021-2032) Figure 51. China Avastin (Bevacizumab) Biosimilars Revenue Share by Type (2021-2032) Figure 52. China Avastin (Bevacizumab) Biosimilars Sales Share by Type (2021-2032) Figure 53. China Avastin (Bevacizumab) Biosimilars Revenue Share by Application (2021-2032) Figure 54. China Avastin (Bevacizumab) Biosimilars Sales Share by Application (2021-2032) Figure 55. Asia Avastin (Bevacizumab) Biosimilars Revenue Share by Type (2021-2032) Figure 56. Asia Avastin (Bevacizumab) Biosimilars Sales Share by Type (2021-2032) Figure 57. Asia Avastin (Bevacizumab) Biosimilars Revenue Share by Application (2021-2032) Figure 58. Asia Avastin (Bevacizumab) Biosimilars Sales Share by Application (2021-2032) Figure 59. Asia Avastin (Bevacizumab) Biosimilars Revenue Share by Country (2021-2032) Figure 60. Asia Avastin (Bevacizumab) Biosimilars Sales Share by Country (2021-2032) Figure 61. SAMEA Avastin (Bevacizumab) Biosimilars Revenue Share by Type (2021-2032) Figure 62. SAMEA Avastin (Bevacizumab) Biosimilars Sales Share by Type (2021-2032) Figure 63. SAMEA Avastin (Bevacizumab) Biosimilars Revenue Share by Application (2021-2032) Figure 64. SAMEA Avastin (Bevacizumab) Biosimilars Sales Share by Application (2021-2032) Fi

Scope & coverage.

Types
  • Cancers
  • AMD
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Biocad
  • Biocon
  • Cadila Pharmaceuticals
  • Centus
  • Dr Reddy's
  • Genentech
  • Hetero
  • Kirin Biologics
  • MAbxience
  • PharmaPraxis
  • PlantForm
  • Samsung Bioepis
  • Sartorius
  • Amgen
  • BeiGene
  • Bayer
  • TOT BIOPHARM
  • Henlius
  • Pfizer
  • Eli Lilly
  • Roche
  • Luye Pharmaceutical
  • Mylan
  • Qilu Pharmaceutical
  • Innovent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Avastin (Bevacizumab) Biosimilars Market by Type
  3. 1.2.1 Global Avastin (Bevacizumab) Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cancers
  5. 1.2.3 AMD
  6. 1.3 Avastin (Bevacizumab) Biosimilars Market by Application
  7. 1.3.1 Global Avastin (Bevacizumab) Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Clinics
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Avastin (Bevacizumab) Biosimilars Market Dynamics
  1. 2.1 Avastin (Bevacizumab) Biosimilars Industry Trends
  2. 2.2 Avastin (Bevacizumab) Biosimilars Industry Drivers
  3. 2.3 Avastin (Bevacizumab) Biosimilars Industry Opportunities and Challenges
  4. 2.4 Avastin (Bevacizumab) Biosimilars Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Avastin (Bevacizumab) Biosimilars Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Region
  3. 3.2.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2021-2026)
  5. 3.2.3 Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2027-2032)
  6. 3.2.4 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Avastin (Bevacizumab) Biosimilars Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Avastin (Bevacizumab) Biosimilars Sales by Region
  9. 3.4.1 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2026)
  11. 3.4.3 Global Avastin (Bevacizumab) Biosimilars Sales by Region (2027-2032)
  12. 3.4.4 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Manufacturers
  2. 4.1.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Avastin (Bevacizumab) Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Avastin (Bevacizumab) Biosimilars Sales by Manufacturers
  6. 4.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Avastin (Bevacizumab) Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Avastin (Bevacizumab) Biosimilars Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Avastin (Bevacizumab) Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Avastin (Bevacizumab) Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Avastin (Bevacizumab) Biosimilars Manufacturers, Product Type & Application
  13. 4.7 Global Avastin (Bevacizumab) Biosimilars Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Avastin (Bevacizumab) Biosimilars Market CR5 and HHI
  16. 4.8.2 2025 Avastin (Bevacizumab) Biosimilars Tier 1, Tier 2, and Tier 3
5 Avastin (Bevacizumab) Biosimilars Market by Type
  1. 5.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Type
  2. 5.1.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Avastin (Bevacizumab) Biosimilars Sales by Type
  6. 5.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2021-2032)
  9. 5.3 Global Avastin (Bevacizumab) Biosimilars Price by Type
6 Avastin (Bevacizumab) Biosimilars Market by Application
  1. 6.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Application
  2. 6.1.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Avastin (Bevacizumab) Biosimilars Sales by Application
  6. 6.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2021-2032)
  9. 6.3 Global Avastin (Bevacizumab) Biosimilars Price by Application
7 Company Profiles
  1. 7.1 Biocad
  2. 7.1.1 Biocad Company Information
  3. 7.1.2 Biocad Business Overview
  4. 7.1.3 Biocad Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio
  6. 7.1.5 Biocad Recent Developments
  7. 7.2 Biocon
  8. 7.2.1 Biocon Company Information
  9. 7.2.2 Biocon Business Overview
  10. 7.2.3 Biocon Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio
  12. 7.2.5 Biocon Recent Developments
  13. 7.3 Cadila Pharmaceuticals
  14. 7.3.1 Cadila Pharmaceuticals Company Information
  15. 7.3.2 Cadila Pharmaceuticals Business Overview
  16. 7.3.3 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio
  18. 7.3.5 Cadila Pharmaceuticals Recent Developments
  19. 7.4 Centus
  20. 7.4.1 Centus Company Information
  21. 7.4.2 Centus Business Overview
  22. 7.4.3 Centus Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Centus Avastin (Bevacizumab) Biosimilars Product Portfolio
  24. 7.4.5 Centus Recent Developments
  25. 7.5 Dr Reddy's
  26. 7.5.1 Dr Reddy's Company Information
  27. 7.5.2 Dr Reddy's Business Overview
  28. 7.5.3 Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio
  30. 7.5.5 Dr Reddy's Recent Developments
  31. 7.6 Genentech
  32. 7.6.1 Genentech Company Information
  33. 7.6.2 Genentech Business Overview
  34. 7.6.3 Genentech Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio
  36. 7.6.5 Genentech Recent Developments
  37. 7.7 Hetero
  38. 7.7.1 Hetero Company Information
  39. 7.7.2 Hetero Business Overview
  40. 7.7.3 Hetero Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio
  42. 7.7.5 Hetero Recent Developments
  43. 7.8 Kirin Biologics
  44. 7.8.1 Kirin Biologics Company Information
  45. 7.8.2 Kirin Biologics Business Overview
  46. 7.8.3 Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio
  48. 7.8.5 Kirin Biologics Recent Developments
  49. 7.9 MAbxience
  50. 7.9.1 MAbxience Company Information
  51. 7.9.2 MAbxience Business Overview
  52. 7.9.3 MAbxience Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio
  54. 7.9.5 MAbxience Recent Developments
  55. 7.10 PharmaPraxis
  56. 7.10.1 PharmaPraxis Company Information
  57. 7.10.2 PharmaPraxis Business Overview
  58. 7.10.3 PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio
  60. 7.10.5 PharmaPraxis Recent Developments
  61. 7.11 PlantForm
  62. 7.11.1 PlantForm Company Information
  63. 7.11.2 PlantForm Business Overview
  64. 7.11.3 PlantForm Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio
  66. 7.11.5 PlantForm Recent Developments
  67. 7.12 Samsung Bioepis
  68. 7.12.1 Samsung Bioepis Company Information
  69. 7.12.2 Samsung Bioepis Business Overview
  70. 7.12.3 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio
  72. 7.12.5 Samsung Bioepis Recent Developments
  73. 7.13 Sartorius
  74. 7.13.1 Sartorius Company Information
  75. 7.13.2 Sartorius Business Overview
  76. 7.13.3 Sartorius Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio
  78. 7.13.5 Sartorius Recent Developments
  79. 7.14 Amgen
  80. 7.14.1 Amgen Company Information
  81. 7.14.2 Amgen Business Overview
  82. 7.14.3 Amgen Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio
  84. 7.14.5 Amgen Recent Developments
  85. 7.15 BeiGene
  86. 7.15.1 BeiGene Company Information
  87. 7.15.2 BeiGene Business Overview
  88. 7.15.3 BeiGene Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio
  90. 7.15.5 BeiGene Recent Developments
  91. 7.16 Bayer
  92. 7.16.1 Bayer Company Information
  93. 7.16.2 Bayer Business Overview
  94. 7.16.3 Bayer Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio
  96. 7.16.5 Bayer Recent Developments
  97. 7.17 TOT BIOPHARM
  98. 7.17.1 TOT BIOPHARM Company Information
  99. 7.17.2 TOT BIOPHARM Business Overview
  100. 7.17.3 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio
  102. 7.17.5 TOT BIOPHARM Recent Developments
  103. 7.18 Henlius
  104. 7.18.1 Henlius Company Information
  105. 7.18.2 Henlius Business Overview
  106. 7.18.3 Henlius Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio
  108. 7.18.5 Henlius Recent Developments
  109. 7.19 Pfizer
  110. 7.19.1 Pfizer Company Information
  111. 7.19.2 Pfizer Business Overview
  112. 7.19.3 Pfizer Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio
  114. 7.19.5 Pfizer Recent Developments
  115. 7.20 Eli Lilly
  116. 7.20.1 Eli Lilly Company Information
  117. 7.20.2 Eli Lilly Business Overview
  118. 7.20.3 Eli Lilly Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio
  120. 7.20.5 Eli Lilly Recent Developments
  121. 7.21 Roche
  122. 7.21.1 Roche Company Information
  123. 7.21.2 Roche Business Overview
  124. 7.21.3 Roche Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Roche Avastin (Bevacizumab) Biosimilars Product Portfolio
  126. 7.21.5 Roche Recent Developments
  127. 7.22 Luye Pharmaceutical
  128. 7.22.1 Luye Pharmaceutical Company Information
  129. 7.22.2 Luye Pharmaceutical Business Overview
  130. 7.22.3 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
  132. 7.22.5 Luye Pharmaceutical Recent Developments
  133. 7.23 Mylan
  134. 7.23.1 Mylan Company Information
  135. 7.23.2 Mylan Business Overview
  136. 7.23.3 Mylan Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio
  138. 7.23.5 Mylan Recent Developments
  139. 7.24 Qilu Pharmaceutical
  140. 7.24.1 Qilu Pharmaceutical Company Information
  141. 7.24.2 Qilu Pharmaceutical Business Overview
  142. 7.24.3 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
  144. 7.24.5 Qilu Pharmaceutical Recent Developments
  145. 7.25 Innovent
  146. 7.25.1 Innovent Company Information
  147. 7.25.2 Innovent Business Overview
  148. 7.25.3 Innovent Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio
  150. 7.25.5 Innovent Recent Developments
8 North America
  1. 8.1 North America Avastin (Bevacizumab) Biosimilars Market Size by Type
  2. 8.1.1 North America Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032)
  3. 8.1.2 North America Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032)
  4. 8.1.3 North America Avastin (Bevacizumab) Biosimilars Price by Type (2021-2032)
  5. 8.2 North America Avastin (Bevacizumab) Biosimilars Market Size by Application
  6. 8.2.1 North America Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032)
  7. 8.2.2 North America Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032)
  8. 8.2.3 North America Avastin (Bevacizumab) Biosimilars Price by Application (2021-2032)
  9. 8.3 North America Avastin (Bevacizumab) Biosimilars Market Size by Country
  10. 8.3.1 North America Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Avastin (Bevacizumab) Biosimilars Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Avastin (Bevacizumab) Biosimilars Market Size by Type
  2. 9.1.1 Europe Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032)
  3. 9.1.2 Europe Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032)
  4. 9.1.3 Europe Avastin (Bevacizumab) Biosimilars Price by Type (2021-2032)
  5. 9.2 Europe Avastin (Bevacizumab) Biosimilars Market Size by Application
  6. 9.2.1 Europe Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032)
  7. 9.2.2 Europe Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032)
  8. 9.2.3 Europe Avastin (Bevacizumab) Biosimilars Price by Application (2021-2032)
  9. 9.3 Europe Avastin (Bevacizumab) Biosimilars Market Size by Country
  10. 9.3.1 Europe Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Avastin (Bevacizumab) Biosimilars Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Avastin (Bevacizumab) Biosimilars Market Size by Type
  2. 10.1.1 China Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032)
  3. 10.1.2 China Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032)
  4. 10.1.3 China Avastin (Bevacizumab) Biosimilars Price by Type (2021-2032)
  5. 10.2 China Avastin (Bevacizumab) Biosimilars Market Size by Application
  6. 10.2.1 China Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032)
  7. 10.2.2 China Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032)
  8. 10.2.3 China Avastin (Bevacizumab) Biosimilars Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Avastin (Bevacizumab) Biosimilars Market Size by Type
  2. 11.1.1 Asia Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032)
  3. 11.1.2 Asia Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032)
  4. 11.1.3 Asia Avastin (Bevacizumab) Biosimilars Price by Type (2021-2032)
  5. 11.2 Asia Avastin (Bevacizumab) Biosimilars Market Size by Application
  6. 11.2.1 Asia Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032)
  7. 11.2.2 Asia Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032)
  8. 11.2.3 Asia Avastin (Bevacizumab) Biosimilars Price by Application (2021-2032)
  9. 11.3 Asia Avastin (Bevacizumab) Biosimilars Market Size by Country
  10. 11.3.1 Asia Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Avastin (Bevacizumab) Biosimilars Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Avastin (Bevacizumab) Biosimilars Market Size by Type
  2. 12.1.1 SAMEA Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Avastin (Bevacizumab) Biosimilars Price by Type (2021-2032)
  5. 12.2 SAMEA Avastin (Bevacizumab) Biosimilars Market Size by Application
  6. 12.2.1 SAMEA Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Avastin (Bevacizumab) Biosimilars Price by Application (2021-2032)
  9. 12.3 SAMEA Avastin (Bevacizumab) Biosimilars Market Size by Country
  10. 12.3.1 SAMEA Avastin (Bevacizumab) Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Avastin (Bevacizumab) Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Avastin (Bevacizumab) Biosimilars Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Avastin (Bevacizumab) Biosimilars Value Chain Analysis
  2. 13.1.1 Avastin (Bevacizumab) Biosimilars Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Avastin (Bevacizumab) Biosimilars Production Mode & Process
  6. 13.2 Avastin (Bevacizumab) Biosimilars Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Avastin (Bevacizumab) Biosimilars Distributors
  9. 13.2.3 Avastin (Bevacizumab) Biosimilars Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst